Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal study of Brilacidin for Oral Mucositis

Next Previous
Trial Profile

A pivotal study of Brilacidin for Oral Mucositis

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brilacidin (Primary)
  • Indications Stomatitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Innovation Pharmaceuticals

    • Most Recent Events

    • 28 Mar 2019 According to an Innovation Pharmaceuticals media release, the European Medicines Agency (EMA) has granted a meeting with the Company's European subsidiary, IPIX Pharma Ltd., to discuss a briefing package submitted for Scientific Advice regarding the clinical development program of Brilacidin oral rinse to decrease the incidence of Severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation.
    • 15 Mar 2019 According to an Innovation Pharmaceuticals media release, the company has completed the necessary documentation to the European Medicines Agency (EMA), requesting Scientific Advice to advance Brilacidin oral rinse in a Phase 3 program for the prevention of severe Oral Mucositis (OM) in Head and Neck Cancer (HNC) patients receiving chemoradiation.
    • 02 Jan 2019 According to an Innovation Pharmaceuticals media release, the company expects to initiate this study in 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top